Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (248)	6/3/2008 8:13:44 AM
From: IRWIN JAMES FRANKEL	of 285

Cardiome Pharma Corp. K I L L K I L L K I L L -- Cardiome Pharma Corp. Tuesday June 3, 4:32 am ET VANCOUVER, June 3 /PRNewswire-FirstCall/ - Editors are advised to disregard TO249, "TEST - Jay 14 - Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor", transmitted at 00:13 today, but dated May 28. This story was transmitted by CNW Group Ltd. in error and should not be used. CONTACT: CNW Group Ltd., 416-863-2130

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next